Conmed (CNMD) Tops Q4 EPS by 1c, Offers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
CONMED (CNMD) PT Lowered to $79 at Needham & Company
January 23, 2019 7:34 AM ESTNeedham & Company analyst Mike Matson lowered the price target on CONMED (NASDAQ: CNMD) to $79.00 (from $86.00) while maintaining a Buy rating.
The analyst commented, "CNMD's 4Q18 revenue beat consensus while its EPS was in line with consensus. Management provided 2019 revenue and EPS guidance that... More
